内容

目次

I. Cancer Drug Development Cancer Drug Development: Challenges in a Competitive Market Barry Greene and Michael Kauffman II. Chemistry and Cell Biology of the Proteasome Introduction to the Proteasome and Its Inhibitors: Biochemistry and Cell Biology Alfred L. Goldberg Structures of the Yeast Proteasome Core Particle in Complex with Inhibitors Michael Groll and Robert Huber Natural Product and Synthetic Proteasome Inhibitors Kyung Bo Kim and Craig M. Crews Other Proteasome Inhibitors Carlos García-Echeverría The Proteasome in Cell-Cycle Regulation Julian Adams Proteasome Inhibition and Apoptosis Simon A. Williams and David J. McConkey The Proteasome and the COMPARE Algorithm Susan L. Holbeck and Edward A. Sausville III. Rationale for Proteasome Inhibitors in Cancer The Proteasome in Cancer Biology and Therapy Frank Pajonk and William H. McBride Radiosensitization and Proteasome Inhibition Carter Van Waes, John B. Sunwoo, William DeGraff, and James B. Mitchell Proteasome-Dependent Regulation of NF-kB Activation: Molecular Targeting of Chemotherapy Resistance James C. Cusack, Jr. Bortezomib with Taxanes Leonard Liebes, Bruce Ng, Yi-He Ling, and Roman Perez-Soler Proteasome Inhibitor Therapy in a Brain Tumor Model Jeffrey J. Olson, Geoffrey Bowers, and Zhaobin Zhang Anthracyclines and Bortezomib Robert Z. Orlowski TNF-Related Apoptosis-Inducing Ligand (TRAIL): Combination with Proteasome Inhibition For Anticancer Therapy? Thomas J. Sayers Rationale for Combining the Proteasome Inhibitor Bortezomib with Cisplatin Edward G. Mimnaugh and Leonard M. Neckers The Effects of the HIV-1 Protease Inhibitor Ritonavir on Proteasome Activity and Antigen Presentation Marcus Groettrup, Rita deGiuli, and Gunter Schmidtke Function(s) of the Ubiquitin-Proteasome System in Retrovirus Budding Ulrich Schubert IV. Clinical Trials Preclinical Development of Bortezomib (VELCADE™): Rationale for Clinical Studies Julian Adams, Peter J. Elliott, and Page Bouchard Phase I Trials: Bortezomib Alone and in Combination With Standard Chemotherapies Dixie-Lee W. Esseltine and David P. Schenkein Clinical Molecular Diagnostics for Proteasome Inhibitors in Cancer Therapy Jeffrey S. Ross, Gerald P. Linette, Geoffrey S. Ginsburg, William Trepicchio, Oscar Kashala, Rebecca Mosher, Jeffrey Brown, George Mulligan, Jim Deeds, and James Stec Phase II Trials of Bortezomib for the Treatment of Multiple Myeloma Kenneth C. Anderson Index